Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review

Osteoporosis International

Volumn 26, Issue 8, 2015, Pages 2073-2089

  Palermo, A ^a   D'Onofrio L ^a   Eastell, R ^b   Schwartz, A V ^c   Pozzilli, P ^a,d   Napoli, N ^a,e  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

BMD; Bone turnover markers; Diabetes; Fracture; Oral anti diabetic drugs; Osteoporosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

BONE DENSITY; BONE METABOLISM; BONE STRENGTH; BONE TURNOVER; CLINICAL TRIAL (TOPIC); DRUG EFFECT; FRAGILITY FRACTURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; BONE REMODELING; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; OSTEOPOROTIC FRACTURES;

ADMINISTRATION, ORAL; BONE DENSITY; BONE REMODELING; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OSTEOPOROTIC FRACTURES; RISK FACTORS;

EID: 84938980132     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3123-0     Document Type: Review

References (156)

1. IDF (2013) IDF Diabetes Atlas, 6th edn
2. Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the european union: medical management, epidemiology and economic burden. A report prepared in collaboration with the international osteoporosis foundation (IOF) and the European federation of pharmaceutical industry associations (EFPIA). Arch Osteoporos 8:136. doi:10.1007/s11657-013-0136-1
3. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18:427–444. doi:10.1007/s00198-006-0253-4
4. Ma L, Oei L, Jiang L et al (2012) Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 27:319–332. doi:10.1007/s10654-012-9674-x
5. Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495–505. doi:10.1093/aje/kwm106
6. Burghardt AJ, Issever AS, Schwartz AV et al (2010) High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95:5045–5055. doi:10.1210/jc.2010-0226
7. Farr JN, Drake MT, Amin S et al (2014) In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 29:787–795. doi:10.1002/jbmr.2106
8. Giangregorio LM, Leslie WD, Lix LM et al (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27:301–308. doi:10.1002/jbmr.556
9. Schwartz AV, Garnero P, Hillier TA et al (2009) Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 94:2380–2386. doi:10.1210/jc.2008-2498
10. Forsén L, Meyer HE, Midthjell K, Edna TH (1999) Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 42:920–925. doi:10.1007/s001250051248
11. De Liefde II, van der Klift M, de Laet CEDH et al (2005) Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713–1720. doi:10.1007/s00198-005-1909-1
12. Patel S, Hyer S, Tweed K et al (2008) Risk factors for fractures and falls in older women with type 2 diabetes mellitus. Calcif Tissue Int 82:87–91. doi:10.1007/s00223-007-9082-5
13. Oei L, Zillikens MC, Dehghan A et al (2013) High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam study. Diabetes Care 36:1619–1628. doi:10.2337/dc12-1188
14. Kim JH, Choi HJ, Ku EJ, et al (2014) Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab jc20142047. doi: 10.1210/jc.2014-2047
15. Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. doi:10.1007/s00198-012-2074-y
16. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34. doi:10.1016/j.jclinepi.2009.06.006
17. Cortizo AM, Sedlinsky C, McCarthy AD et al (2006) Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 536:38–46. doi:10.1016/j.ejphar.2006.02.030
18. Kanazawa I, Yamaguchi T, Yano S et al (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375:414–419. doi:10.1016/j.bbrc.2008.08.034
19. Jang WG, Kim EJ, Bae I-H et al (2011) Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 48:885–893. doi:10.1016/j.bone.2010.12.003
20. Zhen D, Chen Y, Tang X (2010) Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complicat 24:334–344. doi:10.1016/j.jdiacomp.2009.05.002
21. Molinuevo MS, Schurman L, McCarthy AD et al (2010) Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 25:211–221. doi:10.1359/jbmr.090732
22. Schurman L, McCarthy AD, Sedlinsky C et al (2008) Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 116:333–340. doi:10.1055/s-2007-992786
23. Gao Y, Li Y, Xue J et al (2010) Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 635:231–236. doi:10.1016/j.ejphar.2010.02.051
24. Sedlinsky C, Molinuevo MS, Cortizo AM et al (2011) Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats. Eur J Pharmacol 668:477–485. doi:10.1016/j.ejphar.2011.07.033
25. Wang C, Li H, Chen S-G et al (2012) The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice. J Bone Miner Metab 30:630–637. doi:10.1007/s00774-012-0374-0
26. Tolosa MJ, Chuguransky SR, Sedlinsky C et al (2013) Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin. Diabetes Res Clin Pract 101:177–186. doi:10.1016/j.diabres.2013.05.016
27. Kasai T, Bandow K, Suzuki H et al (2009) Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol 221:740–749. doi:10.1002/jcp.21917
28. Salai M, Somjen D, Gigi R et al (2013) Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study. Bone Joint J 95-B:1575–1580. doi:10.1302/0301-620X.95B11.31158
29. Mai Q-G, Zhang Z-M, Xu S et al (2011) Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 112:2902–2909. doi:10.1002/jcb.23206
30. Liu L, Zhang C, Hu Y, Peng B (2012) Protective effect of metformin on periapical lesions in rats by decreasing the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin. J Endod 38:943–947. doi:10.1016/j.joen.2012.03.010
31. Wu W, Ye Z, Zhou Y, Tan W-S (2011) AICAR, a small chemical molecule, primes osteogenic differentiation of adult mesenchymal stem cells. Int J Artif Organs 34:1128–1136. doi:10.5301/ijao.5000007
32. Patel JJ, Butters OR, Arnett TR (2014) PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell Biochem Funct. doi:10.1002/cbf.3025
33. Jeyabalan J, Viollet B, Smitham P et al (2013) The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int 24:2659–2670. doi:10.1007/s00198-013-2371-0
34. Zinman B, Haffner SM, Herman WH et al (2010) Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 95:134–142. doi:10.1210/jc.2009-0572
35. Van Lierop AH, Hamdy NAT, van der Meer RW et al (2012) Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol 166:711–6. doi:10.1530/EJE-11-1061
36. Hegazy SK (2014) Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab. doi:10.1007/s00774-014-0581-y
37. Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292–1299. doi:10.1007/s00125-005-1786-3
38. Melton LJ, Leibson CL, Achenbach SJ et al (2008) Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 23:1334–1342. doi:10.1359/jbmr.080323
39. Solomon DH, Cadarette SM, Choudhry NK et al (2009) A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 94:2792–2798. doi:10.1210/jc.2008-2157
40. Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T (2010) Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 28:554–560. doi:10.1007/s00774-010-0160-9
41. Colhoun HM, Livingstone SJ, Looker HC et al (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55:2929–2937. doi:10.1007/s00125-012-2668-0
42. Monami M, Cresci B, Colombini A et al (2008) Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case–control study. Diabetes Care 31:199–203. doi:10.2337/dc07-1736
43. Napoli N, Strotmeyer ES, Ensrud KE et al (2014) Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 57:2057–2065. doi:10.1007/s00125-014-3289-6
44. TODAY Study Group (2013) Treatment effects on measures of body composition in the TODAY clinical trial. Diabetes Care 36:1742–1748. doi:10.2337/dc12-2534
45. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–43. doi:10.1056/NEJMoa066224
46. Kahn SE, Zinman B, Lachin JM et al (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A diabetes outcome progression trial (ADOPT). Diabetes Care 31:845–851. doi:10.2337/dc07-2270
47. Monami M, Dicembrini I, Kundisova L et al (2014) A meta-analysis of the hypoglycemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab. doi:10.1111/dom.12287
48. Johnston SS, Conner C, Aagren M et al (2012) Association between hypoglycaemic events and fall-related fractures in medicare-covered patients with type 2 diabetes. Diabetes Obes Metab 14:634–643. doi:10.1111/j.1463-1326.2012.01583.x
49. Ma P, Gu B, Ma J et al (2010) Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway. Metabolism 59:359–366. doi:10.1016/j.metabol.2009.08.003
50. Ma P, Xiong W, Liu H et al (2011) Extrapancreatic roles of glimepiride on osteoblasts from rat manibular bone in vitro: regulation of cytodifferentiation through PI3-kinases/Akt signalling pathway. Arch Oral Biol 56:307–316. doi:10.1016/j.archoralbio.2010.10.009
51. Fronczek-Sokół J, Pytlik M (2014) Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats. Pharmacol Rep 66:412–417. doi:10.1016/j.pharep.2013.12.013
52. Dormuth CR, Carney G, Carleton B et al (2009) Thiazolidinediones and fractures in men and women. Arch Intern Med 169:1395–1402. doi:10.1001/archinternmed.2009.214
53. Douglas IJ, Evans SJ, Pocock S, Smeeth L (2009) The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 6:e1000154. doi:10.1371/journal.pmed.1000154
54. Feige JN, Gelman L, Michalik L et al (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120–159. doi:10.1016/j.plipres.2005.12.002
55. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527–550
56. Michalik L, Auwerx J, Berger JP et al (2006) International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58:726–741. doi:10.1124/pr.58.4.5
57. Ahmadian M, Suh JM, Hah N et al (2013) PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 19:557–566. doi:10.1038/nm.3159
58. Shockley KR, Lazarenko OP, Czernik PJ et al (2009) PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106:232–246. doi:10.1002/jcb.21994
59. Johnson TE, Vogel R, Rutledge SJ et al (1999) Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 140:3245–3254. doi:10.1210/endo.140.7.6797
60. Suzawa M, Takada I, Yanagisawa J et al (2003) Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat Cell Biol 5:224–230. doi:10.1038/ncb942
61. Akune T, Ohba S, Kamekura S et al (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846–855. doi:10.1172/JCI19900
62. Cho E-S, Kim M-K, Son Y-O et al (2012) The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol Cell 33:173–181. doi:10.1007/s10059-012-2240-z
63. Rzonca SO, Suva LJ, Gaddy D et al (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401–406. doi:10.1210/en.2003-0746
64. Ali AA, Weinstein RS, Stewart SA et al (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226–1235. doi:10.1210/en.2004-0735
65. Wang L, Li L, Gao H, Li Y (2012) Effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone mesenchymal stem cells into adipocytes. J Huazhong Univ Sci Technolog Med Sci 32:530–533. doi:10.1007/s11596-012-0091-x
66. Seth A, Sy V, Pareek A et al (2013) Thiazolidinediones (TZDs) affect osteoblast viability and biomarkers independently of the TZD effects on aromatase. Horm Metab Res 45:1–8. doi:10.1055/s-0032-1321874
67. Liu L, Aronson J, Lecka-Czernik B (2013) Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration. Bone 52:247–258. doi:10.1016/j.bone.2012.09.038
68. Sardone LD, Renlund R, Willett TL et al (2011) Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes 60:3271–3278. doi:10.2337/db10-1672
69. Sorocéanu MA, Miao D, Bai X-Y et al (2004) Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203–216. doi:10.1677/joe.1.05723
70. Lazarenko OP, Rzonca SO, Hogue WR et al (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669–2680. doi:10.1210/en.2006-1587
71. Gallagher EJ, Sun H, Kornhauser C et al (2014) The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev 30:191–200. doi:10.1002/dmrr.2466
72. Beck GR, Khazai NB, Bouloux GF et al (2013) The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res 161:145–155. doi:10.1016/j.trsl.2012.08.006
73. Benvenuti S, Cellai I, Luciani P et al (2007) Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 30:RC26–RC30
74. Gustafson B, Eliasson B, Smith U (2010) Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. Diabetologia 53:536–540. doi:10.1007/s00125-009-1615-1
75. Mieczkowska A, Baslé MF, Chappard D, Mabilleau G (2012) Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 287:23517–23526. doi:10.1074/jbc.M111.324814
76. Mabilleau G, Mieczkowska A, Edmonds ME (2010) Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet Med 27:925–932. doi:10.1111/j.1464-5491.2010.03048.x
77. Dutchak PA, Katafuchi T, Bookout AL et al (2012) Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148:556–567. doi:10.1016/j.cell.2011.11.062
78. Yakar S, Courtland H-W, Clemmons D (2010) IGF-1 and bone: new discoveries from mouse models. J Bone Miner Res 25:2543–2552. doi:10.1002/jbmr.234
79. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML et al (2007) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148:903–911. doi:10.1210/en.2006-1121
80. Tsirella E, Mavrakanas T, Rager O et al (2012) Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats. J Physiol Pharmacol 63:201–204
81. Wan Y, Chong L-W, Evans RM (2007) PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13:1496–1503. doi:10.1038/nm1672
82. Sottile V, Seuwen K, Kneissel M (2004) Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329–337. doi:10.1007/s00223-004-0224-8
83. Syversen U, Stunes AK, Gustafsson BI et al (2009) Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 9:10. doi:10.1186/1472-6823-9-10
84. Krause U, Harris S, Green A et al (2010) Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci U S A 107:4147–4152. doi:10.1073/pnas.0914360107
85. Rubin GL, Zhao Y, Kalus AM, Simpson ER (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60:1604–1608
86. Seto-Young D, Paliou M, Schlosser J et al (2005) Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 90:6099–6105. doi:10.1210/jc.2005-0469
87. Seto-Young D, Avtanski D, Parikh G et al (2011) Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. Horm Metab Res 43:250–256. doi:10.1055/s-0030-1270525
88. Grey A, Bolland M, Gamble G et al (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305–1310. doi:10.1210/jc.2006-2646
89. Harsløf T, Wamberg L, Møller L et al (2011) Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab 96:1541–1548. doi:10.1210/jc.2010-2077
90. Berberoglu Z, Yazici AC, Demirag NG (2010) Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol (Oxf) 73:305–312. doi:10.1111/j.1365-2265.2010.03784.x
91. Berberoglu Z, Gursoy A, Bayraktar N et al (2007) Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92:3523–3530. doi:10.1210/jc.2007-0431
92. Gruntmanis U, Fordan S, Ghayee HK et al (2010) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 86:343–349. doi:10.1007/s00223-010-9352-5
93. Bilezikian JP, Josse RG, Eastell R et al (2013) Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 98:1519–1528. doi:10.1210/jc.2012-4018
94. Xiao W-H, Wang Y-R, Hou W-F et al (2013) The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes. Int J Endocrinol 2013:290734. doi:10.1155/2013/290734
95. Kanazawa I, Yamaguchi T, Yano S et al (2010) Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int 21:2013–2018. doi:10.1007/s00198-009-1161-1
96. Glintborg D, Andersen M, Hagen C et al (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 93:1696–1701. doi:10.1210/jc.2007-2249
97. Li H, Cui R, Cai H et al (2010) The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes. J Bone Miner Metab 28:77–81. doi:10.1007/s00774-009-0104-4
98. Nybo M, Preil SR, Juhl HF et al (2011) Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. Basic Clin Pharmacol Toxicol 109:481–485. doi:10.1111/j.1742-7843.2011.00752.x
99. Park JS, Cho MH, Nam JS et al (2011) Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol 164:69–74. doi:10.1530/EJE-10-0875
100. Bone HG, Lindsay R, McClung MR et al (2013) Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 98:4691–4701. doi:10.1210/jc.2012-4096
101. Grey A, Bolland M, Fenwick S et al (2014) The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol 170:255–262. doi:10.1530/EJE-13-0793
102. Schwartz AV, Sellmeyer DE, Vittinghoff E et al (2006) Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354
103. Betteridge DJ (2011) Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabet Med 28:759–771. doi:10.1111/j.1464-5491.2010.03187.x
104. Habib ZA, Havstad SL, Wells K et al (2010) Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95:592–600. doi:10.1210/jc.2009-1385
105. Meier C, Kraenzlin ME, Bodmer M et al (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820–825. doi:10.1001/archinte.168.8.820
106. Aubert RE, Herrera V, Chen W et al (2010) Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 12:716–721. doi:10.1111/j.1463-1326.2010.01225.x
107. Bilik D, McEwen LN, Brown MB et al (2010) Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 95:4560–4565. doi:10.1210/jc.2009-2638
108. Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180:32–39. doi:10.1503/cmaj.080486
109. Toulis KA, Goulis DG, Anastasilakis AD (2009) Thiazolidinedione use and the risk of fractures. CMAJ 180:841–842. doi:10.1503/cmaj.1090003, author reply 842–3
110. Hsiao F-Y, Mullins CD (2010) The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case–control study. Diabetologia 53:489–496. doi:10.1007/s00125-009-1609-z
111. Jones SG, Momin SR, Good MW et al (2009) Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care 15:491–496
112. Bazelier MT, Vestergaard P, Gallagher AM et al (2012) Risk of fracture with thiazolidinediones: disease or drugs? Calcif Tissue Int 90:450–457. doi:10.1007/s00223-012-9591-8
113. Zhu Z-N, Jiang Y-F, Ding T (2014) Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68:115–123. doi:10.1016/j.bone.2014.08.010
114. Yaturu S, Bryant B, Jain SK (2007) Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30:1574–1576. doi:10.2337/dc06-2606
115. Borges JLC, Bilezikian JP, Jones-Leone AR et al (2011) A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 d. Diabetes Obes Metab 13:1036–1046. doi:10.1111/j.1463-1326.2011.01461.x
116. Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135. doi:10.1016/S0140-6736(09)60953-3
117. Mancini T, Mazziotti G, Doga M et al (2009) Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45:784–788. doi:10.1016/j.bone.2009.06.006
118. Bray GA, Smith SR, Banerji MA et al (2013) Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes Obes Metab 15:931–937. doi:10.1111/dom.12099
119. Grey A, Beckley V, Doyle A et al (2012) Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. Eur J Endocrinol 166:1087–1091. doi:10.1530/EJE-11-1075
120. Chappard D, Moquereau M, Mercier P et al (2004) Ex vivo bone mineral density of the wrist: influence of medullar fat. Bone 34:1023–1028. doi:10.1016/j.bone.2004.02.002
121. Dormandy J, Bhattacharya M, van Troostenburg De Bruyn A-R (2009) Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 32:187–202
122. Nissen SE, Nicholls SJ, Wolski K et al (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299:1561–1573. doi:10.1001/jama.299.13.1561
123. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705. doi:10.1016/S0140-6736(06)69705-5
124. Pacheco-Pantoja EL, Ranganath LR, Gallagher JA et al (2011) Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol 11:12. doi:10.1186/1472-6793-11-12
125. Kim J-Y, Lee S-K, Jo K-J et al (2013) Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci 92:533–540. doi:10.1016/j.lfs.2013.01.001
126. Nuche-Berenguer B, Portal-Núñez S, Moreno P et al (2010) Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol 225:585–592. doi:10.1002/jcp.22243
127. Sanz C, Vázquez P, Blázquez C et al (2010) Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol Endocrinol Metab 298:E634–E643. doi:10.1152/ajpendo.00460.2009
128. Nuche-Berenguer B, Moreno P, Esbrit P et al (2009) Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 84:453–461. doi:10.1007/s00223-009-9220-3
129. Nuche-Berenguer B, Lozano D, Gutiérrez-Rojas I et al (2011) GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol 209:203–210. doi:10.1530/JOE-11-0015
130. Ma X, Meng J, Jia M et al (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res 28:1641–1652. doi:10.1002/jbmr.1898
131. Mabilleau G, Mieczkowska A, Irwin N et al (2013) Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor. J Endocrinol 219:59–68. doi:10.1530/JOE-13-0146
132. Raun K, von Voss P, Gotfredsen CF et al (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56:8–15. doi:10.2337/db06-0565
133. Yamada C, Yamada Y, Tsukiyama K et al (2008) The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149:574–579. doi:10.1210/en.2007-1292
134. Sbaraglini ML, Molinuevo MS, Sedlinsky C et al (2014) Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells. Eur J Pharmacol 727C:8–14. doi:10.1016/j.ejphar.2014.01.028
135. Cusick T, Mu J, Pennypacker BL et al (2013) Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione. Diabetes Obes Metab 15:954–957. doi:10.1111/dom.12109
136. Kyle KA, Willett TL, Baggio LL et al (2011) Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 152:457–467. doi:10.1210/en.2010-1098
137. Glorie L, Behets GJ, Baerts L et al (2014) DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Physiol Endocrinol Metab 307:E447–E455. doi:10.1152/ajpendo.00217.2014
138. Bunck MC, Eliasson B, Cornér A et al (2011) Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab 13:374–377. doi:10.1111/j.1463-1326.2010.01355.x
139. Henriksen DB, Alexandersen P, Bjarnason NH et al (2003) Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18:2180–2189. doi:10.1359/jbmr.2003.18.12.2180
140. Henriksen DB, Alexandersen P, Hartmann B et al (2007) Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 40:723–729. doi:10.1016/j.bone.2006.09.025
141. Henriksen DB, Alexandersen P, Hartmann B et al (2009) Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45:833–842. doi:10.1016/j.bone.2009.07.008
142. Gottschalck IB, Jeppesen PB, Hartmann B et al (2008) Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand J Gastroenterol 43:1304–1310. doi:10.1080/00365520802200028
143. Bunck MC, Poelma M, Eekhoff EM et al (2012) Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 4:181–185. doi:10.1111/j.1753-0407.2011.00168.x
144. Mabilleau G, Mieczkowska A, Chappard D (2014) Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials (−1:meta). J Diabetes 6:260–266. doi:10.1111/1753-0407.12102
145. Su B, Sheng H, Zhang M et al (2014) Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. doi:10.1007/s12020-014-0361-4
146. Monami M, Dicembrini I, Antenore A, Mannucci E (2011) Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 34:2474–2476. doi:10.2337/dc11-1099
147. Hirshberg B, Parker A, Edelberg H et al (2013) Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. doi:10.1002/dmrr.2502
148. Tirmenstein M, Dorr TE, Janovitz EB et al (2013) Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. Int J Toxicol 32:336–350. doi:10.1177/1091581813505331
149. Yokono M, Takasu T, Hayashizaki Y et al (2014) SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727C:66–74. doi:10.1016/j.ejphar.2014.01.040
150. Kwon H (2013) Canaglifozin: clinical efficacy and safety. Endocrinol. Metab. Drugs Advis. Comm. Meet. 2013. www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Endocrinol.
151. Ljunggren Ö, Bolinder J, Johansson L et al (2012) Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 14:990–999. doi:10.1111/j.1463-1326.2012.01630.x
152. Bolinder J, Ljunggren O, Johansson L et al (2013) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. doi:10.1111/dom.12189
153. List JF, Woo V, Morales E et al (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:650–657. doi:10.2337/dc08-1863
154. Kohan DE, Fioretto P, Tang W, List JF (2013) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. doi:10.1038/ki.2013.356
155. (2013) INVOKANA® (canaglifozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 1–41
156. Taylor SI, Blau JE RK Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3:8–10. doi: 10.1016/S2213-8587(14)70227-X